Abstract
Ninety-two patients with chronic cerebral arteriosclerosis were selected for a study with Pyridinolcarbamate. Sixty-one cases had a follow-up of 12 months under treatment. The drug improved several symptoms related to the disease, particularly the memory for recent data. The exact mechanism of action is not known, although the author admits either a direct effect upon the brain cells or a decrease in platelet aggregation and adhesiveness.
